Literature DB >> 9008287

Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis.

P T Fawcett1, C D Rosé, K M Gibney, R A Doughty.   

Abstract

Response to treatment with antibiotics was compared with serologic reactivity and clinical symptoms in a pediatric population with presumptive diagnoses of Lyme borreliosis. The population analyzed for this study consisted of a subset of a larger Lyme clinic population being monitored as part of a prospective study on pediatric Lyme borreliosis. All patients resided in an area in which Ixodes scapularis and Borrelia burgdorferi are considered endemic. Serum from patients was tested by enzyme-linked immunosorbent assay and Western blotting. Response to antibiotics was evaluated by members of a pediatric Lyme clinic. Results showed that positive serologic test results correlate with a favorable response to antibiotics, as does the presence of erythema migrans (EM), regardless of serologic status. Seronegative patients without EM had chronic fatigue and arthralgia and/or myalgia as primary symptoms and did not respond to antibiotics, even when multiple courses of treatment were given. These results indicate that serologic tests designed to have high specificity can reliably rule out Lyme borreliosis in patients with chronic symptoms, thus preventing unnecessary treatment with antibiotics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008287      PMCID: PMC170481          DOI: 10.1128/cdli.4.1.85-88.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

Review 1.  Lyme disease. Difficulties in diagnosis and management.

Authors:  B E Ostrov; B H Athreya
Journal:  Pediatr Clin North Am       Date:  1991-06       Impact factor: 3.278

Review 2.  Diagnosis of Lyme disease in children.

Authors:  M A Gerber; E D Shapiro
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

3.  Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles.

Authors:  A C Steere; E Dwyer; R Winchester
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

4.  Frequency and specificity of antibodies that crossreact with Borrelia burgdorferi antigens.

Authors:  P T Fawcett; K M Gibney; C D Rose; S B Dubbs; R A Doughty
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

5.  Lyme disease. NIH gears up to test a hotly disputed theory.

Authors:  E Marshall
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

6.  Maturation of the head of bacteriophage T4. I. DNA packaging events.

Authors:  U K Laemmli; M Favre
Journal:  J Mol Biol       Date:  1973-11-15       Impact factor: 5.469

Review 7.  The many faces and phases of borreliosis II.

Authors:  D C Abele; K H Anders
Journal:  J Am Acad Dermatol       Date:  1990-09       Impact factor: 11.527

8.  Adsorption with a soluble E. coli antigen fraction improves the specificity of ELISA tests for Lyme disease.

Authors:  P T Fawcett; K M Gibney; C D Rose; J D Klein; R A Doughty
Journal:  J Rheumatol       Date:  1991-05       Impact factor: 4.666

9.  Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.

Authors:  G Baranton; D Postic; I Saint Girons; P Boerlin; J C Piffaretti; M Assous; P A Grimont
Journal:  Int J Syst Bacteriol       Date:  1992-07

10.  Use of western blot and enzyme-linked immunosorbent assays to assist in the diagnosis of Lyme disease.

Authors:  C D Rose; P T Fawcett; B H Singsen; S B Dubbs; R A Doughty
Journal:  Pediatrics       Date:  1991-09       Impact factor: 7.124

View more
  2 in total

1.  Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis.

Authors:  P T Fawcett; C D Rosé; K M Gibney; R A Doughty
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

Review 2.  Treatment of Lyme borreliosis.

Authors:  Hermann J Girschick; Henner Morbach; Dennis Tappe
Journal:  Arthritis Res Ther       Date:  2009-12-17       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.